Context Therapeutics (CNTX) News Today $0.91 -0.04 (-4.50%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.91 0.00 (-0.03%) As of 01/31/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Franklin Resources Inc. Acquires Additional Shares in Context Therapeutics Inc.January 27, 2025 | gurufocus.comBreakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted TherapyJanuary 18, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest UpdateContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,530,000 shares, an increase of 55.1% from the December 15th total of 986,300 shares. Based on an average daily volume of 501,500 shares, the short-interest ratio is presently 3.1 days. Currently, 2.6% of the shares of the stock are sold short.January 17, 2025 | marketbeat.comContext Therapeutics Welcomes Andy Pasternak as New Chairman of the BoardJanuary 17, 2025 | msn.comContext Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76January 15, 2025 | finanznachrichten.deD. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)D. Boral Capital restated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Wednesday.January 15, 2025 | marketbeat.comContext doses first patient in Phase 1 clinical trial evaluating CTIM-76January 14, 2025 | markets.businessinsider.comContext Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76January 14, 2025 | globenewswire.comContext Therapeutics Appoints Andy Pasternak As Board ChairmanJanuary 13, 2025 | markets.businessinsider.comContext Therapeutics Inc. Appoints Andy Pasternak as Chairman of the Board to Drive Company's Growth in T Cell Engager DevelopmentJanuary 13, 2025 | quiverquant.comContext Therapeutics Appoints Andy Pasternak as Chairman of the Board of DirectorsJanuary 13, 2025 | globenewswire.comJMP Securities Initiates Coverage of Context Therapeutics (CNTX) with Market Outperform RecommendationJanuary 9, 2025 | msn.comContext Therapeutics (NASDAQ:CNTX) Upgraded to Strong-Buy at Citizens JmpCitizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday.January 9, 2025 | marketbeat.comInnovative Growth Potential: Silvan Tuerkcan’s Buy Rating on Context TherapeuticsJanuary 8, 2025 | markets.businessinsider.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of "Buy" from BrokeragesShares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have been given an average recommendation of "Buy" by the five ratings firms that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1-year tarJanuary 8, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from Analysts at JMP SecuritiesJMP Securities began coverage on Context Therapeutics in a report on Wednesday. They issued an "outperform" rating and a $4.00 target price for the company.January 8, 2025 | marketbeat.comContext Therapeutics (NASDAQ: CNTX)January 7, 2025 | fool.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest Up 22.9% in DecemberContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 986,300 shares, a growth of 22.9% from the November 30th total of 802,800 shares. Based on an average trading volume of 525,700 shares, the days-to-cover ratio is presently 1.9 days. Approximately 1.7% of the shares of the company are short sold.December 31, 2024 | marketbeat.comFranklin Resources Inc. Invests $3.69 Million in Context Therapeutics Inc. (NASDAQ:CNTX)Franklin Resources Inc. bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 1,853,988 shares of the company's stock, valued at approximately $3,6December 25, 2024 | marketbeat.comContext Therapeutics Secures Funding for Cancer Therapy PipelineDecember 2, 2024 | markets.businessinsider.comContext Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Decrease in Short InterestContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 879,600 shares, a decrease of 13.8% from the October 31st total of 1,020,000 shares. Currently, 1.5% of the company's shares are short sold. Based on an average daily volume of 278,800 shares, the days-to-cover ratio is currently 3.2 days.December 1, 2024 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Position Reduced by Great Point Partners LLCGreat Point Partners LLC trimmed its holdings in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 6.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,934,982 shares of the company's stock aNovember 27, 2024 | marketbeat.comD. Boral Capital Initiates Coverage of Context Therapeutics (CNTX) with Buy RecommendationNovember 26, 2024 | msn.comContext Therapeutics (NASDAQ:CNTX) Coverage Initiated at D. Boral CapitalD. Boral Capital began coverage on shares of Context Therapeutics in a research report on Monday. They set a "buy" rating and a $9.00 price target for the company.November 25, 2024 | marketbeat.comContext Therapeutics: Strategic Developments and Financial OutlookNovember 22, 2024 | markets.businessinsider.comPromising Preclinical Data and Strategic Trial Design Support Buy Rating for Context TherapeuticsNovember 12, 2024 | markets.businessinsider.comHC Wainwright Has Bearish Forecast for CNTX FY2024 EarningsContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Context Therapeutics in a research report issued on Thursday, November 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will posNovember 11, 2024 | marketbeat.comContext Therapeutics: A Promising Investment in Innovative Oncology Therapies with Strong Financial PositionNovember 10, 2024 | markets.businessinsider.comContext Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings ResultsContext Therapeutics (NASDAQ:CNTX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11).November 9, 2024 | marketbeat.comContext Therapeutics Announces Q3 2024 Financial Results and Strategic AdvancesNovember 9, 2024 | msn.comContext Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsNovember 6, 2024 | globenewswire.comContext Therapeutics to Engage Investors at November ConferencesOctober 26, 2024 | msn.comContext Therapeutics to Participate in Upcoming Investor Conferences in NovemberOctober 23, 2024 | globenewswire.comContext Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 16, 2024 | finance.yahoo.comContext Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 16, 2024 | globenewswire.comContext Therapeutics (NASDAQ:CNTX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comNantahala Capital Management LLC Buys Shares of 1,935,484 Context Therapeutics Inc. (NASDAQ:CNTX)Nantahala Capital Management LLC purchased a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,935,484 shares of the company's stock, valuOctober 1, 2024 | marketbeat.comDriehaus Capital Management LLC Purchases Shares of 2,258,065 Context Therapeutics Inc. (NASDAQ:CNTX)Driehaus Capital Management LLC acquired a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,258,065 shares of the company'sSeptember 30, 2024 | marketbeat.comBlue Owl Capital Holdings LP Takes $10.35 Million Position in Context Therapeutics Inc. (NASDAQ:CNTX)Blue Owl Capital Holdings LP bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,161,290 shares of the company's stSeptember 28, 2024 | marketbeat.comPiper Sandler Keeps Their Buy Rating on Context Therapeutics (CNTX)September 27, 2024 | markets.businessinsider.comBioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment DevelopmentSeptember 26, 2024 | msn.comHC Wainwright Comments on Context Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:CNTX)Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2024 earnings estimates for Context Therapeutics in a research report issued on Monday, September 23rd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings peSeptember 26, 2024 | marketbeat.comBuy Rating Affirmed for Context Therapeutics Amid Strategic Licensing and Promising TCE Portfolio ExpansionSeptember 25, 2024 | markets.businessinsider.comContext Therapeutics Inc. (NASDAQ:CNTX) Stock Position Lifted by Affinity Asset Advisors LLCAffinity Asset Advisors LLC increased its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 392.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,September 25, 2024 | marketbeat.comGreat Point Partners LLC Purchases Shares of 7,419,355 Context Therapeutics Inc. (NASDAQ:CNTX)Great Point Partners LLC acquired a new position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 7,419,355 shares of the company's stock, valued at approximately $14,876,000. Context TherapeuticsSeptember 24, 2024 | marketbeat.comBioAtla Grants Exclusive, Worldwide License To Context Therapeutics To Develop BA3362September 23, 2024 | markets.businessinsider.comBioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodySeptember 23, 2024 | globenewswire.comContext Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Ally Bridge Group NY LLCAlly Bridge Group NY LLC boosted its position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 159.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,886,232 shares of the company's stock after purSeptember 23, 2024 | marketbeat.comPiper Sandler maintains Overweight rating on Context Therapeutics stockSeptember 19, 2024 | uk.investing.comPositive Outlook for Context Therapeutics’ CTIM-76 Based on ESMO 2024 Data and Buy Rating by Emily BodnarSeptember 16, 2024 | markets.businessinsider.com Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼1.460.69▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼22▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AQST News LFVN News AVIR News RZLT News ACIU News DMAC News CCCC News BNTC News CMPS News CGC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTX Stock Alerts